Paving the Road for Haematopoietic Stem Cell Transplantation in the United Arab Emirates: A Single Centre's Experience.

IF 2.1 Q3 HEMATOLOGY

Journal of Blood Medicine Pub Date : 2024-11-04 eCollection Date: 2024-01-01 DOI:10.2147/JBM.S468665

Panayotis Kaloyannidis, Biju George, Ahmad Alrustamani, Charbel Khalil, Basmah Al-Charfli, Nour Al-Moghrabi, Dima Ibrahim, Mohammed Alfar, Mohammed Daryahya, Kayane Mheidly, Amro El-Saddik, Humaid O Al-Shamsi

{"title":"Paving the Road for Haematopoietic Stem Cell Transplantation in the United Arab Emirates: A Single Centre's Experience.","authors":"Panayotis Kaloyannidis, Biju George, Ahmad Alrustamani, Charbel Khalil, Basmah Al-Charfli, Nour Al-Moghrabi, Dima Ibrahim, Mohammed Alfar, Mohammed Daryahya, Kayane Mheidly, Amro El-Saddik, Humaid O Al-Shamsi","doi":"10.2147/JBM.S468665","DOIUrl":null,"url":null,"abstract":"Background: Despite its long-term history, haematopoietic stem cell transplantation (HSCT) still faces challenges in several countries under development and especially in the private health sector.Objectives design and methods: In this retrospective analysis, we present our experience and the results of 48 adult patients who underwent HSCT (autologous 37, allogeneic 9) at a private-sector hospital in Abu Dhabi, United Arab Emirates (UAE). The main indications were multiple myeloma and acute myeloid leukaemia in the autologous and allogeneic setting, respectively.Results: All patients successfully engrafted, and after a median follow-up of 6 (range: 1-11) months, 42 patients are alive (36 autografted and 6 allografted). The 1-year overall survival rates were 97% and 62% for autografted and allografted patients, respectively, while 4 patients died within 100 days post-transplant from treatment-related causes (1 patient from the autografted group and 3 patients from the allografted group).Conclusion: Our data confirm that HSCT is a feasible, safe, and effective treatment approach, offering high success rates to UAE patients with haematological malignant diseases.","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"471-475"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546142/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/JBM.S468665","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite its long-term history, haematopoietic stem cell transplantation (HSCT) still faces challenges in several countries under development and especially in the private health sector.

Objectives design and methods: In this retrospective analysis, we present our experience and the results of 48 adult patients who underwent HSCT (autologous 37, allogeneic 9) at a private-sector hospital in Abu Dhabi, United Arab Emirates (UAE). The main indications were multiple myeloma and acute myeloid leukaemia in the autologous and allogeneic setting, respectively.

Results: All patients successfully engrafted, and after a median follow-up of 6 (range: 1-11) months, 42 patients are alive (36 autografted and 6 allografted). The 1-year overall survival rates were 97% and 62% for autografted and allografted patients, respectively, while 4 patients died within 100 days post-transplant from treatment-related causes (1 patient from the autografted group and 3 patients from the allografted group).

Conclusion: Our data confirm that HSCT is a feasible, safe, and effective treatment approach, offering high success rates to UAE patients with haematological malignant diseases.

查看原文本刊更多论文

为阿拉伯联合酋长国的造血干细胞移植铺平道路：单个中心的经验。

背景：尽管造血干细胞移植（HSCT）历史悠久，但在一些发展中的国家，尤其是私营医疗部门，仍面临着挑战：在这项回顾性分析中，我们介绍了在阿拉伯联合酋长国（阿联酋）阿布扎比一家私立医院接受造血干细胞移植（自体37例，异体9例）的48名成年患者的经验和结果。主要适应症为多发性骨髓瘤和急性髓性白血病，分别为自体和异体移植：所有患者均成功移植，中位随访 6 个月（1-11 个月）后，42 名患者存活（36 名自体移植，6 名异体移植）。自体移植和异体移植患者的1年总生存率分别为97%和62%，4名患者在移植后100天内因治疗相关原因死亡（自体移植组1人，异体移植组3人）：我们的数据证实造血干细胞移植是一种可行、安全且有效的治疗方法，可为阿联酋血液恶性疾病患者提供高成功率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Blood Medicine HEMATOLOGY-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all topics pertaining to blood based medicine including but not limited to: Transfusion Medicine (blood components, stem cell transplantation, apheresis, gene based therapeutics), Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics, Immunohematology, Artificial and alternative blood based therapeutics, Hematology including disorders/pathology related to leukocytes/immunology, red cells, platelets and hemostasis, Biotechnology/nanotechnology of blood related medicine, Legal aspects of blood medicine, Historical perspectives. Original research, short reports, reviews, case reports and commentaries are invited.